Effect of Risperidone Combined with Buspirone on Clinical Efficacy and Safety in Patients with First-episode Schizophrenia
Objective:To explore the clinical value of Risperidone combined with Buspirone on clinical efficacy and safety in patients with first-episode schizophrenia.Method:A total of 70 patients with first-stage schizophrenia admitted to Department of Psychiatry Ⅱ,Oasis Hospital,Shihezi from February 2021 to September 2023 were selected as the study objects,and they were divided into the control group(received Risperidone monotherapy)and the study group(combined with Buspirone therapy on the basis of the control group)according to random number table method,with 35 cases in each group.The efficacy,degree of clinical symptoms,lipid metabolism indexes and adverse reactions were compared between the two groups.Result:The total effective rate of the study group(97.14%)was higher than that of the control group(77.14%),the difference was statistically significant(x2=6.248,P=0.012).Before treatment,there were no significant differences in the degree of clinical symptoms between the two groups(P>0.05).After treatment,the degree of clinical symptoms in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).There were no significant differences in triglyceride and total cholesterol between the two groups before and after treatment(P>0.05).There was no significant difference in the adverse reaction rate between the study group(11.43%)and the control group(17.14%)(x2=2.540,P=0.111).Conclusion:Risperidone combined with Buspirone can improve the therapeutic effect of patients with first-episode schizophrenia,reduce the degree of clinical symptoms,and has a certain safety,without causing abnormal lipid metabolism.
万方数据
维普
